197 related articles for article (PubMed ID: 15650264)
1. Targeting multiple myeloma cells and their bone marrow microenvironment.
Pagnucco G; Cardinale G; Gervasi F
Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Hideshima T; Anderson KC
Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
[TBL] [Abstract][Full Text] [Related]
3. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
Yasui H; Hideshima T; Richardson PG; Anderson KC
Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
[TBL] [Abstract][Full Text] [Related]
7. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
8. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
10. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
[TBL] [Abstract][Full Text] [Related]
11. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Mitsiades CS; Mitsiades NS; Richardson PG; Munshi NC; Anderson KC
J Cell Biochem; 2007 Jul; 101(4):950-68. PubMed ID: 17546631
[TBL] [Abstract][Full Text] [Related]
16. Current status of new drugs for the treatment of patients with multiple myeloma.
Kenealy M; Prince HM
Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
[TBL] [Abstract][Full Text] [Related]
17. [Management of multiple myeloma].
Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
[TBL] [Abstract][Full Text] [Related]
18. Moving disease biology from the laboratory to the clinic.
Anderson KC
Semin Oncol; 2002 Dec; 29(6 Suppl 17):17-20. PubMed ID: 12520480
[TBL] [Abstract][Full Text] [Related]
19. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
20. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
[Next] [New Search]
